Peptide Research Blog
Plain-language reviews of published peptide research. Each article reports what the studies measured, how strong the evidence is, and what it cannot tell you.
Metabolic and Weight, September 25, 2026
Cagrilintide and CagriSema: What the Published Trials Show
Cagrilintide is an amylin analog studied alone and with semaglutide as CagriSema. Here is what three published trials measured, and what they cannot tell you.
Read the articleMetabolic and Weight, September 25, 2026
Retatrutide, Tirzepatide and Semaglutide: What the Trials Measured
Weight-loss figures for three incretin-based drugs look easy to compare. They are not. Here is what each key trial measured and why the numbers do not line up.
Read the articleHealing and Recovery, September 25, 2026
GLOW Peptide Blend: What the Evidence Shows
GLOW is sold under one name but defined differently by different sources. Here is what published research says about GHK-Cu, BPC-157 and TB-500, and what it does not.
Read the article